WAIKOLOA, Hawaii — In this expert perspective from Retina 2026, Michael S. Ip, MD, discusses a study that compared intraocular inflammatory events and side effects in patients treated with aflibercept 2 mg, aflibercept 8 mg and faricimab.
Ip, of Doheny Eye Center UCLA Arcadia, said there were “slightly higher” intraocular inflammatory (IOI) events with Eylea HD (aflibercept 8 mg, Regeneron) and Vabysmo (faricimab-svoa, Genentech).
“Much remains to be determined with these kinds of real-world studies, but it is tantalizing to see that maybe there is some increased IOI